Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bifidobacterium breve CCFM1026
- Development stage
- Preclinical
- Lead developer
- Nanjing Agricultural University
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
CCFM1026 is a probiotic bacterial strain, specifically *Bifidobacterium breve* CCFM1026, investigated as a research-stage biological intervention against Influenza A virus (IAV) infection. It is not a conventional pharmaceutical drug but rather a live probiotic microorganism. Its active ingredient is the live bacterial strain *Bifidobacterium breve* CCFM1026, and its antiviral mechanism is attributed to its metabolite butyrate, which modulates immune responses including the TLR7/MyD88/TRAF6/TNF-α signaling pathway, reduces neutrophil proportions, and increases lymphocytes. It has been studied in mouse models of influenza A (H1N1) infection, where it alleviated lung inflammation and restored immune balance. The research originates from Chinese academic and patent literature, specifically associated with Jiangnan University.
- Other names
- Bifidobacterium breve CCFM1026
02
Targets
TLR7 (Toll-like receptor 7)TNFA (Tumor necrosis factor alpha (soluble))TRAF6MYD88 (Myeloid differentiation primary response protein MyD88)
Beyond the preview
Go deeper on Bifidobacterium breve CCFM1026.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bifidobacterium breve CCFM1026.